Studies on FAM13A regulatory mechanisms have moved from human COPD [16], fibrosis of the lung [36], and NSCLC [26,37], to insulin sensitivity [38], adipocyte differentiation [19,23], and proliferation [39,40], and the correlation between the hypoxic state and other aspects [35,37,41]. Here, FAM13A is linked to chronic obstructive pulmonary disease.